Paper Details

  1. Home
  2. Paper Details

Examination of haematotoxicity of fixed-dose highly active antiretroviral drug in albino wistar rats.

Author: NubilaNkoyo I, NubilaThomas, OkorieGodfrey I, UkaejiofoErnest O

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

A study on Albino Wistar rats evaluating the haematotoxic effects of lamivudine, zidovudine, and nevirapine fixed-dose combinations found no subacute haematotoxic effects.
Paper Details　
Original Abstract of the Article :
Highly active antiretroviral therapy (HAART) is considered toxic and has other life-threatening side effects. Our aim was to evaluate the haematotoxic effects of lamivudine, zidovudine, and nevirapine fixed-dose combinations in Albino Wistar rats. Fifty (50) three (3) months old male Albino Wistar r...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3544270/

データ提供：米国国立医学図書館（NLM）

Exploring the Hematotoxicity of Antiretroviral Therapy: A Rat Study

Highly active antiretroviral therapy (HAART) has revolutionized the treatment of HIV infection, but its potential side effects, including hematotoxcity, remain a concern. This study investigated the hematotoxic effects of a fixed-dose combination of lamivudine, zidovudine, and nevirapine in rats.

Reassuring Findings on Hematotoxicity

The results of this study provide reassuring evidence that HAART, when administered in fixed-dose combinations, does not exhibit subacute hematotoxic effects in rats. This finding contributes to the understanding of the safety profile of HAART regimens.

Navigating HIV Treatment with Confidence

This research adds to the growing body of knowledge about the safety and efficacy of HAART. Like a camel navigating a treacherous desert landscape, patients with HIV need reliable and safe treatment options to ensure their long-term health and well-being.

Dr.Camel's Conclusion

This study provides evidence that fixed-dose combinations of HAART do not have subacute hematotoxic effects in rats. The findings contribute to the understanding of the safety profile of these vital treatments for HIV infection.

Date :
  1. Date Completed 2013-01-18
  2. Date Revised 2021-10-21
Further Info :

Pubmed ID

23326679

DOI: Digital Object Identifier

PMC3544270

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.